An Oakland biotech startup pared its workforce by 60% and implemented other cost reduction initiatives to extend the company’s operating runway into the second quarter of 2024.
NeuBase Therapeutics Inc., which also has offices in Cambridge, Mass., said the cost-saving measures had been implemented by Sept. 30, the end of its fiscal year. Among the belt tightening measures was slowing the company’s development of gene silencing programs for Huntington’s disease, myotonic dystrophy and cancers driven by common gene mutations.
NeuBase’s development of those technologies was entering more costly stages as broader capital markets for small biotech companies tightened, according to the company.
For the fiscal year ending Sept. 30, Neubase reported a net loss of $33.8 million, a 38% increase from a loss of $25.4 million that was reported for the same period a year ago. During the same 12 months, operating expenses rose 25% to $33.3 million from $26.6 million last fiscal year.
Driving up the losses was the asset acquisition of Vera Therapeutics Inc., a Brisbane, Calif.-based clinical stage biotech company. Terms of the deal were not disclosed.
The net yearly losses pushed down the price of a NeuBase share into the red by $1.04 from a loss of 93 cents for the same period a year ago.
Neubase, which was founded in 2009 and acquired by Ohr Pharmaceutical Inc., a New York City-based pharma company in 2019, is developing technologies that modulate that machinery that controls gene function. Nearly all diseases are caused by genetic changes, the company said.
Kris B. Mamula: kmamula@post-gazette.com







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.